Lv12
70 积分 2025-12-23 加入
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
4天前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
12天前
已完结
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
12天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
12天前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
18天前
已完结
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies
19天前
已完结
First-line Therapy in Newly Diagnosed Multiple Myeloma
1个月前
已完结
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
1个月前
已完结
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
1个月前
已完结
How I Treat Plasma Cell Leukemia
1个月前
已完结
皖公网安备34019202002308
